These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 517491)
1. The double-blind crossover trial design: how good is it for psychoactive drugs? Brahen LS; Capone T; Wojak JC Am J Drug Alcohol Abuse; 1979; 6(2):189-96. PubMed ID: 517491 [No Abstract] [Full Text] [Related]
2. Prospects, problems, side effects, and safety of narcotic antagonists. Resnick RB Int J Addict; 1977 Oct; 12(7):863-7. PubMed ID: 591144 [TBL] [Abstract][Full Text] [Related]
3. Naltrexone and cyclazocine. A controlled treatment study. Brahen LS; Capone T; Wiechert V; Desiderio D Arch Gen Psychiatry; 1977 Oct; 34(10):1181-4. PubMed ID: 911218 [TBL] [Abstract][Full Text] [Related]
4. Evolution of the National Academy of Sciences study of naltrexone. Kaim SC NIDA Res Monogr; 1976 Sep; (9):37-44. PubMed ID: 794719 [No Abstract] [Full Text] [Related]
5. Clinical experiences with naltrexone in 370 detoxified addicts. Thomas M; Kauders F; Harris M; Cooperstein J; Hough G; Resnick R NIDA Res Monogr; 1976 Sep; (9):88-92. PubMed ID: 794726 [TBL] [Abstract][Full Text] [Related]
6. Naltrexone for opioid addiction. Med Lett Drugs Ther; 1985 Feb; 27(680):11-2. PubMed ID: 3969057 [No Abstract] [Full Text] [Related]
7. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone. Schecter A Am J Drug Alcohol Abuse; 1980; 7(1):1-18. PubMed ID: 6254356 [No Abstract] [Full Text] [Related]
8. Cyclazocine in the treatment of opiate addiction: a review with recommendations. Goldstein MJ Int J Addict; 1980 Oct; 15(7):939-56. PubMed ID: 6256300 [TBL] [Abstract][Full Text] [Related]
9. NIDA's naltrexone research program. Julius D NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943 [No Abstract] [Full Text] [Related]
10. Naltrexone, opiate addiction, and endorphins. Gold MS; Dackis CA; Pottash AL; Sternbach HH; Annitto WJ; Martin D; Dackis MP Med Res Rev; 1982; 2(3):211-46. PubMed ID: 6289026 [No Abstract] [Full Text] [Related]
11. Naltrexone-induced dysphoria in former opioid addicts. Crowley TJ; Wagner JE; Zerbe G; Macdonald M Am J Psychiatry; 1985 Sep; 142(9):1081-4. PubMed ID: 2992300 [TBL] [Abstract][Full Text] [Related]
12. Cyclazocine-induced sleep disruptions in nondependent addicts. Pickworth WB; Neidert GL; Kay DC Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(1):77-85. PubMed ID: 3010383 [TBL] [Abstract][Full Text] [Related]
13. Predictors of favorable outcome following naltrexone treatment. Greenstein RA; Evans BD; McLellan AT; O'Brien CP NIDA Res Monogr; 1983 Apr; 43():294-301. PubMed ID: 6410264 [No Abstract] [Full Text] [Related]
14. Abstinence treatments for opiate addicts: therapeutic community or naltrexone? Arndt I; McLellan AT; O'Brien CP NIDA Res Monogr; 1984 Mar; 49():275-81. PubMed ID: 6434972 [No Abstract] [Full Text] [Related]
15. Assessment of naltrexone in the treatment of schizophrenia. Gitlin MJ; Gerner RH; Rosenblatt M Psychopharmacology (Berl); 1981; 74(1):51-3. PubMed ID: 6791204 [TBL] [Abstract][Full Text] [Related]
16. Comments and findings from a naltrexone double blind study. Keegan J; Lavenduski C; Schooff K NIDA Res Monogr; 1976 Sep; (9):74-6. PubMed ID: 794724 [No Abstract] [Full Text] [Related]
17. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Judson BA; Carney TM; Goldstein A Drug Alcohol Depend; 1981 Jul; 7(4):325-46. PubMed ID: 7023894 [TBL] [Abstract][Full Text] [Related]